SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Marker Therapeutics, Inc. (MRKR) News

Follow Marker Therapeutics, Inc. (MRKR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MRKR Asset equity Sector Markets 90 days 4 Last 1.11 Updated Nov 19, 2026, 12:01 PM UTC Open live news feed Open MRKR chart & news
M Marker Therapeutics Awarded $16.2 Million CPRIT Grant The grant will advance MT-601 in the Phase 2 APOLLO study. EQUITY | Nov 19, 2026, 12:01 PM UTC M Marker Therapeutics Awarded $16.2 Million CPRIT Grant for MT-601 Study The grant will advance MT-601 in the Phase 2 APOLLO study. EQUITY | Nov 19, 2026, 12:00 PM UTC L Marker Therapeutics awarded $2.6 million FDA grant for pancreatic cancer program The FDA awarded Marker Therapeutics a $2.6 million Orphan Products Development grant to advance MT-601 in pancreatic cancer. EQUITY | Oct 19, 2026, 11:08 AM UTC L MRKR - Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies MRKR - Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies NEWS | Sep 22, 2026, 12:02 PM UTC